- Profesionales sanitarios
- Estudios e investigación
- Publicación de artículos
- SBRT Differs Systemic Therapy in Prostate Cancer with Lymph Node Oligometastases
2023-04-02T08:00:00.000+10:00
SBRT Differs Systemic Therapy in Prostate Cancer with Lymph Node Oligometastases
SBRT Differs Systemic Therapy in Prostate Cancer with Lymph Node Oligometastases
Cureus
/es/profesionales-sanitarios/estudios-e-investigacion/publicacion-de-articulos/sbrt-differs-systemic-therapy-in-prostate-cancer-with-lymph-node
Oncología Radioterápica
Written by
Luis Larrea, Paola Antonini, Enrique Lopez, Jose Lago, Maria-Carmen Baños, Verónica González
Luis Larrea, Paola Antonini, Enrique Lopez, Jose Lago, Maria-Carmen Baños, Verónica González:::
Abstract
Objectives:
To evaluate the results of the use of stereotactic body radiation therapy (SBRT or SABR) for prostate cancer (PC) lymph node oligometastases, in terms of biochemical control, local control and toxicity.
Conclusions
The low toxicity and high local control observed in our series, add to the evidence of a possible role of SBRT in the management of selected patients affected by oligometastatic lymph node prostate cancer relapse, The good biochemical control results might lead to a decrease or delay in the use of systemic/hormonal treatments in this subset of patients. Longer follow up is needed to validate if there is also a favorable impact on survival.